• PRIYANKA DAS Department of pharmaceutics, Girijananda Chowdhury Institute of Pharmaceutical, Science, Hattkhowapara, Azara, Guwahati 781017



Diabetes, Insulin, Oral delivery, Insulin inhalers, Buccal delivery, Transdermal delivery, Insulin devices


Diabetes mellitus is a chronic metabolic disorder caused via the deficiency of pancreatic hormone insulin (Type1 diabetes mellitus) or due to the resistance of cells to insulin secreted by using the body (Type 2 diabetes mellitus). It is a rapidly growing serious situation that inspires a lot of global concern. Exogenous insulin administration is many times used therapy for Type 1 Diabetes Mellitus and gestational diabetes. The traditional subcutaneous insulin injections cause a lot of suffering to the affected person, exceptionally due to pain and secondarily due to dose sensitivity and in additional complications. Hence alternate delivery systems are an area of recreation for medical professionals and a convenient alternative system will be a boon to the patients. As an end result of the technological advances, various invasive and non-invasive delivery systems have been brought in the previous years. Nanotechnology, particle-mediated delivery, pulmonary delivery, buccal spray, etc. are the most current advances.


Download data is not yet available.


1. Jaleh Varshosaz. Insulin delivery systems for controlling diabetes-recent patents on endocrine. Metab Immune Drug Discovery 2007;1:25-40.
2. Vaughan M, Hill RL. The discovery of insulin: the work of frederick banting and charles best. J Biol Chem 2002;277:e15.
3. Fisher M, Frier BM. Diabetes mellitus in Davidson's principles and practice of medicine; 2006.
4. Rosenfeld L. Insulin: discovery and controversy. Clin Chem 2002;48:2270-88.
5. Yaturu S. Current and future trends at dawn: insulin therapies. World J Diabetes 2013;4:1-7.
6. Chen KJ, Chen MC, Sung HW, Sonaje K. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials 2011;32:9826-38.
7. Garmel G, Martinez R. Gas gangrene from subcutaneous insulin administration. Am J Emerg Med 1993;11:622-5.
8. Lin CK, Sonaje K, Lin KJ, Yeh TH. Biodistribution, pharmacodynamics, and pharmacokinetics of insulin analogs in a rat model: oral delivery using pH-responsive nanoparticles vs. subcutaneous injection. Biomaterials 2010;31:6849-58.
9. Arbit E. The physiological rationale for oral insulin administration. Diabetes Technol Ther 2004;6:510-7.
10. Chowdhury EH, Ahmad A, Zaini A, Othman I. Oral nano-insulin therapy: current progress on nanoparticle-based devices for intestinal epithelium-targeted insulin delivery. J Nanomed Nanotechnol 2012:S4-007. DOI:10.4172/2157-7439.S4-007
11. Bargman JM. Intraperitoneal versus subcutaneous insulin in patients on nighttime IPD. Adv Perit Dial 1994;10:116-9.
12. Carvalho RA, Woitiski CB, Veiga F, Neufeld RJ, Figueiredo IV. Pharmacological effect of orally delivered insulin facilitated b multilayered stable NPs. Eur J Pharm Sci 2010;41:556-63.
13. Woitiski CB, Carvalho RA, Sarmento B, Veiga F, Neufeld RJ. Facilitated nanoscale delivery of insulin across intestinal membrane models. Int J Pharm 2011;412:123-31.
14. Nature S. Insulin therapies: current and future trends at dawn. World J Diabetes 2013;4:1-7.
15. Zhi ZL, Khan F, Birch DJS, Saxl T. Nanomedicine and it's potential in diabetes research and practice. Diabetes/Metab Res Rev 2008;24:604-10.
16. Lassmann Vague V, Raccah D. Alternatives routes of insulin delivery. Diabetes Metab 2006;32:513-22.
17. Avadi MR, Mohammadpour N, Abedin S, Atyabi F, Sadeghi AMM. Preparation and characterization of insulin NPs using chitosan and Arabic gum with ionic gelation method. Nanomed: Nanotechnol Biol Med 2010;6:58-63.
18. Sonaje K, Hsu LW, Chuang EY, Liao ZX, Chuang EY. pH-Responsive NPS shelled with chitosan for oral delivery of insulin. Mechanism Ther Appl Chem Res 2012;45:619-29.
19. Jintapattanakit A, Kissel T, Mao S, Zetterberg J, Bakowsky U, Junyaprasert VB. Peroral delivery of insulin using chitosan derivatives: A comparative study of polyelectrolyte nanocomplexes and NPs. Int J Pharma 2007;342:240-9.
20. Lim LY, Ma Z, Lim TM. Pharmacological activity of peroral chitosan-insulin NPs in diabetic rats. Int J Pharm 2005;293:271-80.
21. Kundu PP, Mukhopadhyay P, Rana D, Mishra R. Strategies for effective oral insulin delivery with modified chitosan NPs. Progress Polymer Sci 2002;37:1457-75.
22. Jin Y, Song Y, Zhou D, Zhang Z, Zhu X, Chen C. Goblet cell-targeting NPS for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials 2012;33:1573-82.
23. Sonaje K, Lin YH, Juang JH, Wey SP, Chen CT, Sung HW. In vivo evaluation of safety and efficacy of self-assembled NPs for oral insulin delivery. Biomaterials 2009;30:2329-39.
24. Sonaje K, Nguyen HN, Hsu CW, Chen YJ, Chen HL, Wey SP, Juang JH. Enteric-coated capsules filled with freeze-dried chitosan/poly(?-glutamic acid)NPs for oral insulin delivery. Biomaterials 2010;31:3384-94.
25. Sajeesh S, Ponchel G, Sharma CP, Vauthier C, Gueutin C. Thiol functionalized polymethacrylic acid-based hydrogel microparticles for oral insulin delivery. Acta Biomater 2010;6:3072-80.
26. Tang C, Yin C, Cui F, Qian F, Zhao Z, Yin L. Preparation, characterization, and oral delivery of insulin-loaded carboxylated chitosan grafted poly(methyl methacrylate) NPs. Biomacromolecules 2009;10:1253-8.
27. Woitiski CB, Ribeiro A, Neufeld R, Veiga F. Design for optimization of NPS integrating biomaterials for orally dosed insulin. Eur J Pharm Biopharm 2009;73:25-33.
28. Veiga F, Ferreira D, Sarmento B, Riberio A. Development and characterization of new insulin-containing polysaccharide NPs. Colloids Surfaces 2006;53:193-202.
29. Chalasani KB, Jain AK, Diwan PV, Jain SK, Russell Jones GJ. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran NPs. J Controlled Release 2007;112:141-50.
30. Chalasani KB, Yandrapu SK, Diwan PV, Russell Jones GJ. A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. J Controlled Release 2007;425:421-9.
31. Wu ZM, Qian Y, Luo KQ, Zhang LJ, Zhou L, Guo XD, et al. HP55-coated capsule containing PLGA/RS NPs for oral delivery of insulin. Int J Pharm 2012;425:1-8.
32. Cun DM, Zhang LQ, Cui FD, Tao AJ. Preparation of insulin-loaded PLGAHP55NPS for oral delivery. J Pharma Sci 2007;96:421-7.
33. Xiong XY, Zhou CL, Tam KC, Li YP, Li ZL. Vesicles from pluronic/poly(lactic acid) block copolymers as new carriers for oral insulin delivery. J Controlled Release 2007;120:11-7.
34. Ubrich N, Damge C, Maincent P. Oral delivery of insulin associated with polymeric NPS in diabetic rats. J Controlled Release 2007;117:163-70.
35. Liu J, Zhang Z, Gong T, Zhong Z, Wang C. Solid lipid NPs loaded with insulin by sodium cholate-phosphatidylcholine–based mixed micelles: Preparation and characterization. Int J Pharm 2007;340:153-62.
36. Rajiv Dhand, Vamsi P. Guntur-inhaled insulin: extending the horizons of inhalation therapy. Respiratory Care 2007;52:911-22.
37. S Chauhan Nitesh, Singh Vijender, Chauhan Sanjeev, Handa Vandana. Recent advances in insulin delivery systems: an update. World Appl Sci J 2010;11:1552-6.
38. R Kumria, G Goomber. Emerging trends in insulin delivery; buccal route. J Diabet 2011;2:1-8.
39. Jaleh Varshosaz. Insulin delivery systems for controlling diabetes-recent patents endocrine. Metab Immune Drug Discovery 2007;1:25-40.
40. Patel Binal, R Pandey Shivanand, NP Jivan, Choudhary Amruta, Mahalakshmi, Devmurari Viral. Pulmonary delivery as a route for insulin. Int J PharmTech Res 2009;1:1190-7.
41. Todd C Zion, Jackie Y Ying, Henry H Tsang. Glucose-sensitive nanoparticles for controlled insulin delivery. Available from: [Last accessed on 05 Oct 2020].
42. Valerie Ravaine, Bogdan Catargi, Christophe Ancla. Chemically controlled closed-loop insulin delivery. J Controlled Release 2008;132:2-11.
43. AH Clemens. Programmable open loopmicropump insulin delivery system. Diab Care 1980;3:359-61.
44. Lassmann Vague V, Raccah D. Alternatives routes of insulin delivery. Diabetes Metabol 2006;32:513-22.
45. Garcia Contreras L, Hickey AJ, Morçöl T, Bell SJD. Evaluation of novel particles as pulmonary delivery systems for insulin in rats. AAPS PharmSciTech 2003;5:1.
46. Sharma JPK, Bansal S, Banik A. Noninvasive routes of proteins and peptides drug delivery. Indian J Pharm Sci 2011;73:367-75.
47. Hosny E, Al-Shora HI, Elmazar MM. Relative hypoglycemic effect of insulin suppositories in diabetic beagle dogs: optimization of various concentrations of sodium salicylate and polyoxyethylene-9-lauryl ether. Biol Pharm Bull 2001;24:1294-7.
48. Shashank Shah. Novel drug delivery carrier: resealed erythrocytes. Int J Pharm Biosci 2001;2:394-406.
49. Tarun Garg, Onkar Singh, Saahil Arora, RSR Murthy. Dendrimer a novel scaffolding for drug delivery. Int J Pharm Sci Rev Res 2011;7:211-20.



How to Cite

DAS, P. “NANOPARTICLE INSULIN DRUG DELIVERY-APPLICATIONS AND NEW ASPECTS”. International Journal of Current Pharmaceutical Research, vol. 13, no. 2, Mar. 2021, pp. 1-5, doi:10.22159/ijcpr.2021v13i2.41582.



Review Article(s)